PCRX - Pacira BioSciences records 17.7% sequential growth in August revenue

• Pacira BioSciences ( NASDAQ: PCRX ) stated Tuesday that its preliminary net product sales rose 17.7% sequentially during the month to $59.1M for Aug. 2022; up 108% year-over-year.
• It includes: EXPAREL net product sales, $46.7M; ZILRETTA sales, $9.7M; and iovera° net product sales, $1.5M.
• Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $1.2M in Aug. 2022.
• "August sales were highlighted by year-over-year growth trends improving in the second half of the month and EXPAREL surpassing the 11 million patient mark," said Dave Stack, chairman and chief executive officer of Pacira BioSciences.
• Earlier: Pacira meets key goal in late-stage trial to expand label for local anesthetic

For further details see: